### ü´Å Critical Care Medicine: Right Lung Atelectasis from Endobronchial Obstruction

#### ‚úÖ True Statements
1. **Atelectasis** is the loss of gas within the lung with a resultant decrease in lung volume.
2. Significant **atelectasis** may cause an **ipsilateral mediastinal shift**.
3. **Right lung atelectasis** can be caused by an obstruction within the **right mainstem bronchus**, such as an **endobronchial tumor** or a **large mucous plug**.
4. **Massive pleural effusion** can cause complete opacification of a hemithorax but does **not** cause ipsilateral mediastinal deviation; instead, if large enough, it causes **contralateral displacement** of mediastinal structures.
5. **Pneumonia** is unlikely to cause mediastinal shift.

#### üí¨ Extra
2. In the case described, atelectasis of the right lung caused a rightward mediastinal shift, demonstrated by displacement of the trachea and left mainstem bronchus.
4. This distinction between atelectasis and effusion helps differentiate causes of a completely opacified hemithorax.

#### üè∑Ô∏è Tags
#CriticalCare #HospitalCare #Atelectasis #BronchialObstruction #MucousPlug #ChestRadiograph

#### üìö Reference
MKSAP 19, Critical Care Medicine. Educational Objective: Diagnose right lung atelectasis secondary to endobronchial obstruction.

#### üÜî Question ID
CCVDX24005

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
Critical Care Medicine ‚Äî Common ICU Conditions ‚Äî Acute Respiratory Failure

---

### üìò Related Text Derivations

#### ‚úÖ True Statements ‚Äî Acute Respiratory Failure (Definition & Evaluation)
1. **Acute respiratory failure** occurs when oxygenation of blood is inadequate (**hypoxemia**) or removal of carbon dioxide (**hypercapnia**) is inadequate.
2. A structured evaluation for acute respiratory failure includes **history**, **physical examination**, **chest radiography**, **computed tomography (CT)**, **arterial blood gas (ABG) analysis**, and **pulse oximetry**.
3. The structured approach includes assessment for **airway compromise**, **inadequate oxygenation**, and **inadequate ventilation**.

#### üí¨ Extra
2. The radiographic and algorithmic elements referenced include the **Radiographic Findings in Acute Respiratory Failure** table and the **Acute Respiratory Failure Assessment** figure.

---

#### ‚úÖ True Statements ‚Äî Acute Upper Airway Management
1. In patients unable to **maintain a patent airway** or **protect against aspiration**, **intubation with a cuffed endotracheal tube** under **direct or indirect laryngoscopy** is the **standard of care**.
2. A **2023 multicenter randomized trial** in critically ill patients found that **video laryngoscopy** **increased first-pass success** compared with **direct laryngoscopy**.
3. **Oropharyngeal**, **nasopharyngeal**, or **supraglottic** devices (e.g., **laryngeal mask airway**) can aid **oxygenation** and **ventilation** when immediate intubation is not feasible and may be used **as a bridge** until the airway is secured.
4. **Obstruction or compression** of the upper airway can cause respiratory failure.
5. **Partial airway obstruction** may present with **tachypnea**, **stridor**, **increased respiratory effort**, or **upright (tripod) posture** with **accessory muscle use**.
6. **Complete obstruction** is suggested by **absent air movement**, **inability to talk**, or **cyanosis**.
7. **Inspiratory stridor** suggests obstruction **at or above the vocal cords**; **expiratory stridor/wheezing** suggests an **intrathoracic** process.
8. In **partial upper airway obstruction with stridor**, **pulse oximetry is usually normal** and **should not be considered reassuring**.
9. In patients with **respiratory distress** or **high risk of deterioration**, **early intubation** is indicated.

#### üí¨ Extra
2. The trial population was **critically ill**; the outcome was **successful intubation**.

---

#### ‚úÖ True Statements ‚Äî Hypoxemic Respiratory Failure
1. **Hypoxemic respiratory failure** results from **inadequate oxygenation of hemoglobin**.
2. The condition is most often due to **shunt**, an extreme **ventilation‚Äìperfusion (V/Q) mismatch** where **V/Q = 0** and **perfused lung is not ventilated**.
3. The two main causes of **shunt** are **alveolar collapse (atelectasis)** and **alveolar filling** with **blood**, **cells**, **protein**, or **water**.
4. Less commonly, **shunt** results from **fistulas** or **cardiac/pulmonary vessel malformations**.
5. A key feature of **shunt** is an **increased alveolar‚Äìarterial (A-a) oxygen gradient** that is **not responsive to oxygen supplementation**.
6. **V/Q mismatch** may also increase the **A-a gradient**, whereas **hypoxemia from alveolar hypoventilation** should have a **normal A-a gradient**.
7. The **alveolar gas equation** is: **Alveolar P**O‚ÇÇ = *(F**I**O‚ÇÇ √ó [P**atm** ‚àí 47]) ‚àí (1.25 √ó P**CO‚ÇÇ*)*.
8. In the equation, **F**I**O‚ÇÇ** is the **fraction of inspired oxygen** (0.21 in ambient air), **P**atm** is **atmospheric pressure** (760 mm Hg at sea level), and **47 mm Hg** is the **water vapor pressure** at **37.0 ¬∞C (98.6 ¬∞F)**.
9. Clinical features of **acute hypoxemic respiratory failure** include **recent onset of increased work of breathing**, **tachypnea**, and **anxiety**; **cyanosis** of **lips/fingers** may be present with severe desaturation.
10. **Auscultation findings** (e.g., **crackles**, **wheezing**, **egophony**, **rhonchi**) and **chest imaging** may help identify the cause.
11. **Clubbing** suggests **chronic diseases** such as **bronchiectasis**, **idiopathic pulmonary fibrosis**, or **lung cancer**.
12. Treatment of **hypoxemic respiratory failure** includes **supplemental oxygen**, **mechanical ventilation with positive end-expiratory pressure (PEEP)** to **open alveoli**, and, in severe cases, **extracorporeal membrane oxygenation (ECMO)**.

#### üí¨ Extra
7‚Äì8. The **A-a gradient** is obtained by **subtracting measured arterial P**O‚ÇÇ from **calculated alveolar P**O‚ÇÇ using the equation**, then comparing with the expected value based on **age** and **F**I**O‚ÇÇ**.

---

#### ‚úÖ True Statements ‚Äî Acute Inhalational Injuries
1. **Pulmonary complications** are a **leading cause of morbidity and mortality** after **burns** or **significant smoke exposure**.
2. **Direct thermal injury** from **smoke inhalation** usually involves the **upper airways**.
3. **Steam inhalation** can cause **direct thermal injury** throughout the **tracheobronchial tree** because **steam carries heat more efficiently** than dry hot gas.
4. After smoke inhalation, **~one third** of patients develop **airway edema** or **mucosal sloughing** from **epithelial necrosis**.
5. **Early intubation**, **chest physiotherapy**, and **serial bronchoscopy** are frequently necessary to facilitate **airway clearance**.
6. Chemicals in smoke can injure the **distal tracheobronchial tree** and **lung parenchyma**, causing **bronchoconstriction**, **pulmonary edema**, **V/Q mismatch**, and **bronchial cast formation**; **treatment is supportive**.
7. **Secondary infections** after smoke inhalation are **common** and are a **major cause of morbidity and mortality**.
8. **Pneumonia** is the **most common complication** after smoke inhalation, especially due to **Staphylococcus** and **Pseudomonas** species.
9. **Carbon monoxide** and **hydrogen cyanide** toxicity are **common** after smoke exposure and should be **suspected in all exposed patients**.
10. **Chemical vapor injuries** occur in **war**, **industry**, **farming**, and **home cleaning/pesticide** exposures.
11. **Water-soluble agents** usually affect **upper airway mucosa** with **rapid symptom onset**; **water-insoluble agents** affect **deeper structures** (lung parenchyma/distal airways) with **often delayed symptoms**.
12. **Edema**, **bronchospasm**, **asphyxiation**, and **direct systemic toxicity** are **common** effects of chemical inhalation injuries.
13. In **cholinesterase inhibitor (organophosphate) exposure**, **high-dose atropine** is given **until bronchorrhea and bronchospasm are controlled**.
14. **E-cigarette‚Äì or vaping-associated lung injury (EVALI)** is linked to **vitamin E acetate** used to **thicken illicit vaping products**.
15. Clinical suspicion for **EVALI** should be **high** in users of **e-cigarettes/vaping devices** who have **hypoxemia** with **respiratory** (cough, dyspnea) and **gastrointestinal** (abdominal pain, vomiting, diarrhea) symptoms; **fever/chills** may occur.
16. Reported **EVALI cases** **declined sharply since 2019** after **public awareness** increased and **vitamin E acetate** was removed from affected products.
17. **Treatment of EVALI** is **supportive**; **empiric antibiotics** are often given if **infection cannot be ruled out**.
18. **Systemic glucocorticoids** may be **useful in severe EVALI**.

---

#### üìñ Related Text
MKSAP 19: Critical Care Medicine ‚Äî Common ICU Conditions ‚Äî Acute Respiratory Failure (sections: Acute Respiratory Failure; Acute Upper Airway Management; Hypoxemic Respiratory Failure; Acute Inhalational Injuries)

---

### üìò Related Text Derivations

#### ‚úÖ True Statements ‚Äî Acute Respiratory Failure (Definition & Evaluation)
1. **Acute respiratory failure** occurs when oxygenation of blood is inadequate (**hypoxemia**) or removal of carbon dioxide (**hypercapnia**) is inadequate.
2. A structured evaluation for acute respiratory failure includes **history**, **physical examination**, **chest radiography**, **computed tomography (CT)**, **arterial blood gas (ABG) analysis**, and **pulse oximetry**.
3. The structured approach includes assessment for **airway compromise**, **inadequate oxygenation**, and **inadequate ventilation**.

#### üí¨ Extra
2. The radiographic table and assessment algorithm referenced are included below under Supplemental Tables and Figures.

---

#### ‚úÖ True Statements ‚Äî Acute Upper Airway Management
1. In patients unable to **maintain a patent airway** or **protect against aspiration**, **intubation with a cuffed endotracheal tube** under **direct or indirect laryngoscopy** is the **standard of care**.
2. A **2023 multicenter randomized trial** in critically ill patients found that **video laryngoscopy** **increased the likelihood of successful intubation** compared with **direct laryngoscopy**.
3. **Oropharyngeal**, **nasopharyngeal**, or **supraglottic** devices (e.g., **laryngeal mask airway**) can aid **oxygenation** and **ventilation** when immediate intubation is not feasible and may be used **until the airway can be secured**.
4. **Obstruction or compression** of the upper airway can cause respiratory failure.
5. **Partial airway obstruction** may present with **tachypnea**, **stridor**, **increased respiratory effort**, or **upright (tripod) posture** with **accessory muscle use**.
6. **Complete obstruction** is suggested by **absent air movement**, **inability to talk**, or **cyanosis**.
7. **Inspiratory stridor** suggests obstruction **at or above the vocal cords**; **expiratory stridor and wheezing** suggest an **intrathoracic process**.
8. In **partial upper airway obstruction with stridor**, **pulse oximetry is usually normal** and **should not be interpreted as reassuring**.
9. In patients with **respiratory distress** or **high risk of deterioration**, **early intubation** is indicated.

#### üí¨ Extra
2. The trial population was **critically ill** and the outcome was **successful intubation** on initial attempt.

---

#### ‚úÖ True Statements ‚Äî Hypoxemic Respiratory Failure
1. **Hypoxemic respiratory failure** results from **inadequate oxygenation of hemoglobin**.
2. The condition is most often due to **shunt**, an extreme **ventilation‚Äìperfusion (V/Q) mismatch** where **V/Q = 0** and **perfused lung is not ventilated**.
3. The two main causes of **shunt** are **alveolar collapse (atelectasis)** and **alveolar filling** with **blood**, **cells**, **protein**, or **water**.
4. Less commonly, **shunt** results from **fistulas** or **cardiac/pulmonary vessel malformations**.
5. A key feature of **shunt** is an **increased alveolar‚Äìarterial (A-a) oxygen gradient** that is **not responsive to oxygen supplementation**.
6. **V/Q mismatch** may also increase the **A-a gradient**, whereas **hypoxemia from alveolar hypoventilation** should have a **normal A-a gradient**.
7. The **alveolar gas equation** is: **Alveolar P**O‚ÇÇ = *(F**I**O‚ÇÇ √ó [P**atm** ‚àí 47]) ‚àí (1.25 √ó P**CO‚ÇÇ*)*.
8. In the equation, **F**I**O‚ÇÇ** is the **fraction of inspired oxygen** (0.21 in ambient air), **P**atm** is **atmospheric pressure** (760 mm Hg at sea level), and **47 mm Hg** is the **water vapor pressure** at **37.0 ¬∞C (98.6 ¬∞F)**.
9. Clinical features of **acute hypoxemic respiratory failure** include **recent onset of increased work of breathing**, **tachypnea**, and **anxiety**; **cyanosis** of **lips/fingers** may be present with severe desaturation.
10. **Auscultation findings** (e.g., **crackles**, **wheezing**, **egophony**, **rhonchi**) and **chest imaging** may help identify the cause.
11. **Clubbing** suggests **chronic diseases** such as **bronchiectasis**, **idiopathic pulmonary fibrosis**, or **lung cancer**.
12. Treatment of **hypoxemic respiratory failure** includes **supplemental oxygen**, **mechanical ventilation with positive end-expiratory pressure (PEEP)** to **open alveoli**, and, in severe cases, **extracorporeal membrane oxygenation (ECMO)**.

#### üí¨ Extra
7‚Äì8. The **A-a gradient** is obtained by subtracting measured arterial P**O‚ÇÇ** from calculated alveolar P**O‚ÇÇ** and comparing with expected values based on **age** and **F**I**O‚ÇÇ**.

---

#### ‚úÖ True Statements ‚Äî Acute Inhalational Injuries
1. **Pulmonary complications** are a **leading cause of morbidity and mortality** after **burns** or **significant smoke exposure**.
2. **Direct thermal injury** from **smoke inhalation** usually involves the **upper airways**.
3. **Steam inhalation** can cause **direct thermal injury** throughout the **tracheobronchial tree** because **steam carries heat more efficiently** than dry hot gas.
4. After smoke inhalation, **approximately one third** of patients develop **airway edema** or **mucosal sloughing** from **epithelial necrosis**.
5. **Early intubation**, **chest physiotherapy**, and **serial bronchoscopy** are frequently necessary to facilitate **airway clearance**.
6. Chemicals in smoke can injure the **distal tracheobronchial tree** and **lung parenchyma**, causing **bronchoconstriction**, **pulmonary edema**, **V/Q mismatch**, and **bronchial cast formation**; **treatment is supportive**.
7. **Secondary infections** after smoke inhalation are **common** and are a **major cause of morbidity and mortality**.
8. **Pneumonia** is the **most common complication** after smoke inhalation, especially due to **Staphylococcus** and **Pseudomonas** species.
9. **Carbon monoxide** and **hydrogen cyanide** toxicity are **common** after smoke exposure and should be **suspected in all exposed patients**.
10. **Chemical vapor injuries** occur in **war**, **industry**, **farming**, and **home cleaning/pesticide** exposures.
11. **Water-soluble agents** usually affect **upper airway mucosa** with **rapid symptom onset**; **water-insoluble agents** affect **deeper structures** with **often delayed symptoms**.
12. **Edema**, **bronchospasm**, **asphyxiation**, and **direct systemic toxicity** are **common** effects of chemical inhalation injuries.
13. In **cholinesterase inhibitor (organophosphate) exposure**, **high-dose atropine** is administered **until bronchorrhea and bronchospasm are controlled**.
14. **E-cigarette‚Äì or vaping-associated lung injury (EVALI)** is linked to **vitamin E acetate** used to **thicken illicit vaping products**.
15. Clinical suspicion for **EVALI** should be **high** in users of **e-cigarettes/vaping devices** who have **hypoxemia** with **respiratory** (cough, dyspnea) and **gastrointestinal** (abdominal pain, vomiting, diarrhea) symptoms; **fever/chills** may occur.
16. Reported **EVALI cases** **declined sharply since 2019** after **public awareness** increased and **vitamin E acetate** was removed from affected products.
17. **Treatment of EVALI** is **supportive**; **empiric antibiotics** are often given if **infection cannot be ruled out**.
18. **Systemic glucocorticoids** may be **useful in severe EVALI**.

---

#### üóæ Supplemental Tables

<!-- Common Causes of ARDS -->
<table>
  <caption><strong>Common Causes of Acute Respiratory Distress Syndrome</strong></caption>
  <tbody>
    <tr><th colspan="1">Direct Pulmonary Injury</th></tr>
    <tr><td>Aspiration of gastric contents</td></tr>
    <tr><td>Fat embolism</td></tr>
    <tr><td>Near drowning</td></tr>
    <tr><td>Pneumonia (including viral causes such as COVID-19)</td></tr>
    <tr><td>Smoke or chemical inhalation</td></tr>
    <tr><td>Thoracic trauma/thoracic contusion</td></tr>
    <tr><th colspan="1">Indirect Pulmonary Injury</th></tr>
    <tr><td>Disseminated intravascular coagulation</td></tr>
    <tr><td>Nonthoracic trauma</td></tr>
    <tr><td>Pancreatitis</td></tr>
    <tr><td>Pulmonary reperfusion injury (after lung transplantation)</td></tr>
    <tr><td>Sepsis/septic shock</td></tr>
    <tr><td>Transfusion of blood products</td></tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: Common Causes of ARDS)
1. **Direct pulmonary injury** causes of ARDS include **aspiration of gastric contents**, **fat embolism**, **near drowning**, **pneumonia (including viral causes such as COVID-19)**, **smoke or chemical inhalation**, and **thoracic trauma/contusion**.  
2. **Indirect pulmonary injury** causes of ARDS include **disseminated intravascular coagulation**, **nonthoracic trauma**, **pancreatitis**, **pulmonary reperfusion injury after lung transplantation**, **sepsis/septic shock**, and **transfusion of blood products**.  

---

<!-- 2023 ARDS Definition -->
<table>
  <caption><strong>2023 New Global Definition of Acute Respiratory Distress Syndrome</strong></caption>
  <tbody>
    <tr><td>Acute hypoxemic respiratory failure (within 1 wk)</td></tr>
    <tr><td>If not intubated, high-flow nasal oxygen ‚â•30 L/min or NIV/CPAP ‚â•5 cm H<sub>2</sub>O end-expiratory pressure</td></tr>
    <tr><td>Hypoxemia levels of:<br>
      P<sub>O‚ÇÇ</sub>/F<sub>IO‚ÇÇ</sub> ‚â§300 mm Hg or SpO‚ÇÇ/F<sub>IO‚ÇÇ</sub> &lt;315 mm Hg with SpO‚ÇÇ ‚â§97%</td></tr>
    <tr><td>Bilateral lung opacities confirmed by chest radiograph, CT, or ultrasound with a trained operator</td></tr>
    <tr><td><strong>In resource-limited settings:</strong><br>
      SpO‚ÇÇ/F<sub>IO‚ÇÇ</sub> &lt;315 with SpO‚ÇÇ ‚â§97% (minimum PEEP and oxygen flow rates not required)</td></tr>
  </tbody>
</table>
<p><em>CPAP = continuous positive airway pressure; NIV = noninvasive ventilation; PEEP = positive end-expiratory pressure; SpO‚ÇÇ = oxygen saturation as measured by pulse oximetry.<br>
Recommendations from Matthay MA, Arabi Y, Arroliga AC, et al. A new global definition of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2024;209:37-47. PMID: 37487152</em></p>

#### ‚úÖ True Statements (from Table: 2023 ARDS Definition)
1. The **2023 ARDS definition** requires **acute hypoxemic respiratory failure within 1 week** of an insult.  
2. In non-intubated patients, ARDS can be diagnosed with **high-flow nasal oxygen ‚â•30 L/min** or **NIV/CPAP ‚â•5 cm H‚ÇÇO**.  
3. **Hypoxemia criteria** include **Pao‚ÇÇ/Fio‚ÇÇ ‚â§300 mm Hg** or **SpO‚ÇÇ/Fio‚ÇÇ <315 mm Hg with SpO‚ÇÇ ‚â§97%**.  
4. **Bilateral lung opacities** must be confirmed on **chest radiograph, CT, or ultrasound**.  
5. In **resource-limited settings**, ARDS can be defined as **SpO‚ÇÇ/Fio‚ÇÇ <315 with SpO‚ÇÇ ‚â§97%** without minimum PEEP or flow requirements.  

---

<!-- PEEP‚ÄìFio‚ÇÇ Table -->
<table>
  <caption><strong>PEEP‚ÄìFio‚ÇÇ Table for Selecting PEEP for the Ventilation of Patients with ARDS</strong></caption>
  <thead>
    <tr>
      <th>Fio‚ÇÇ</th>
      <th>0.3</th>
      <th>0.4</th>
      <th>0.4</th>
      <th>0.5</th>
      <th>0.5</th>
      <th>0.6</th>
      <th>0.7</th>
      <th>0.7</th>
      <th>0.8</th>
      <th>0.9</th>
      <th>0.9</th>
      <th>0.9</th>
      <th>1.0</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>PEEP (cm H‚ÇÇO)</th>
      <td>5</td>
      <td>5</td>
      <td>8</td>
      <td>8</td>
      <td>10</td>
      <td>10</td>
      <td>10</td>
      <td>12</td>
      <td>14</td>
      <td>14</td>
      <td>16</td>
      <td>18</td>
      <td>18‚Äì24</td>
    </tr>
  </tbody>
</table>
<p><em>PEEP = positive end-expiratory pressure.<br>
Data from the NIH‚ÄìNational Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network.</em></p>

#### ‚úÖ True Statements (from Table: PEEP‚ÄìFio‚ÇÇ Table)
1. The **PEEP‚ÄìFio‚ÇÇ table** provides recommended **PEEP levels** for varying **Fio‚ÇÇ requirements** in ARDS ventilation.  
2. At **Fio‚ÇÇ 0.3**, recommended **PEEP** is **5 cm H‚ÇÇO**.  
3. At **Fio‚ÇÇ 0.5**, recommended **PEEP** is **8‚Äì10 cm H‚ÇÇO**.  
4. At **Fio‚ÇÇ 0.7**, recommended **PEEP** is **10‚Äì12 cm H‚ÇÇO**.  
5. At **Fio‚ÇÇ 1.0**, recommended **PEEP** is **18‚Äì24 cm H‚ÇÇO**.  

---

### üñºÔ∏è Supplemental Figure

<figure>
  <img src="Diffuse Alveolar Damage in ARDS.jpg" alt="Histology of diffuse alveolar damage in ARDS" />
  <figcaption><strong>ARDS Histology Showing Diffuse Alveolar Damage</strong><br>
  1 = interstitial edema (thickened cellular space between airspace and vasculature);<br>
  2 = hyaline membranes (proteinaceous alveolar exudates that accumulate along alveolar surfaces and impair gas exchange);<br>
  3 = denuded epithelium (type 1 alveolar cell loss with replacement by hyaline membrane or fibrosis).</figcaption>
</figure>

#### ‚úÖ True Statements (from Figure: Diffuse Alveolar Damage in ARDS)
1. **Interstitial edema** in ARDS involves **thickening of the cellular space** between alveoli and vasculature.  
2. **Hyaline membranes** in ARDS are **proteinaceous alveolar exudates** that line alveolar surfaces and impair gas exchange.  
3. **Denuded epithelium** in ARDS reflects **loss of type 1 alveolar cells**, replaced by **hyaline membrane or fibrosis**.  

---

### üìò Related Text Derivations

---

#### ‚úÖ True Statements ‚Äî Pulmonary Embolism
1. **Pulmonary embolism (PE)** causes respiratory failure primarily through **ventilation‚Äìperfusion (V/Q) mismatch**.  
2. After acute **PE**, resistance to pulmonary blood flow increases due to **thrombosis** and **vasospasm** of adjacent pulmonary vessels mediated by inflammation.  
3. In **PE**, blood is redirected to normal lung regions, which may become **overperfused**.  
4. **Hypoxemia** occurs if alveolar oxygen levels in overperfused normal lung are insufficient to oxygenate blood.  
5. **Shunt physiology** contributes to hypoxemia in **PE** when blood flows through **atelectatic lung**.  
6. In **PE** with significant pulmonary arterial obstruction, **right ventricular (RV) strain** and **decreased cardiac output** may occur.  
7. When **RV strain** occurs in conjunction with **V/Q mismatch** and **shunt**, oxygenation of blood before leaving alveolar capillaries is impaired, worsening **hypoxemia**.  
8. Most patients with hypoxemia after **PE** can be managed with **supplemental oxygen alone**.  
9. Some patients with **PE** require **intubation and mechanical ventilation**.  
10. **Mechanical ventilation** in **PE with RV dysfunction** can worsen hemodynamics by:  
    - Increasing **intrathoracic pressure**, reducing **venous return** and **RV preload**.  
    - Increasing **alveolar pressure**, compressing capillaries, and increasing **RV afterload**.  
11. These physiologic effects can worsen **RV dysfunction** and cause **hemodynamic instability** in patients with **PE**.  
12. Although not contraindicated, **mechanical ventilation in PE** requires anticipation of rapid **hemodynamic instability**.  
13. Hemodynamic instability in **PE** is managed with **vasopressors (norepinephrine)**, **oxygen**, careful use of **positive end-expiratory pressure (PEEP)**, and sometimes **pulmonary vasodilators** (inhaled nitric oxide or epoprostenol).  
14. In **PE with hemodynamic collapse**, **thrombolytic therapy** improves clinical parameters and decreases mortality.  
15. **Thrombolytic therapy** in **PE** carries up to a **2% risk of intracranial hemorrhage**.  
16. In **PE** patients with **contraindications to thrombolysis**, or where **thrombolysis has failed**, **surgical or catheter-based embolectomy** is a treatment option.

#### üí¨ Extra
10. The deleterious effects of mechanical ventilation in **PE** are due to both preload reduction and afterload increase, which can precipitate cardiovascular collapse.  
14. The mortality benefit of **thrombolysis** is demonstrated specifically in **hemodynamic collapse from PE**.  

---

### üìò Related Text Derivations

---

#### ‚úÖ True Statements ‚Äî Hypercapnic (Ventilatory) Respiratory Failure
1. **Hypercapnic (ventilatory) respiratory failure** occurs when **alveolar ventilation** is inadequate to clear **carbon dioxide (CO‚ÇÇ)** produced by cellular metabolism, resulting in **elevated arterial PCO‚ÇÇ**.  
2. **Hypercapnia** reflects **alveolar hypoventilation**, an **increased metabolic load** not matched by ventilation, or **both**.  
3. **Alveolar hypoventilation** occurs with **decreased respiratory rate**, **decreased tidal volume (VT)**, or **increased dead-space volume relative to VT (VD/VT)**.  
4. Clinical features of **acute hypercapnic respiratory failure** are **variable** and **nonspecific**; **somnolence** and **myoclonic jerks** can occur with **CO‚ÇÇ narcosis**.  
5. **Increased work of breathing** may precede the development of **acute hypercapnic respiratory failure**.  
6. **Preexisting chest wall deformity, neurologic weakness,** or **polycythemia** should prompt evaluation for **hypercapnia** in the setting of respiratory failure.  
7. Patients with **hypercapnic respiratory failure** frequently have **coexisting hypoxemia**; **supplemental oxygen** may **decrease hypoxemia** but **increase hypercapnia** via **ventilation‚Äìperfusion (V/Q) mismatch**, **decreased respiratory drive**, and the **Haldane effect**.  
8. Worsening **hypercapnia** with oxygen is **particularly problematic** for **neuromuscular diseases**, risking **obtundation** and **respiratory arrest**.  
9. **Arterial blood gas (ABG)** analysis should be obtained in **all suspected acute hypercapnic respiratory failure**, even if **hypoxemia resolves** with oxygen; **pH** helps determine **acuity and severity**.  
10. In **chronic hypercapnia**, **pH changes are less marked** because of **metabolic compensation** with **increased serum bicarbonate**.  
11. Management of **elevated arterial PCO‚ÇÇ** depends on the **clinical context** and **resultant pH**; in **COPD**, elevated PCO‚ÇÇ may be **baseline**, whereas in **asthma**, rising PCO‚ÇÇ may signal **imminent respiratory failure** requiring **emergent intubation**.

#### ‚úÖ True Statements ‚Äî Decreased Respiratory Drive
12. **Decreased respiratory drive** leads to **diminished alveolar CO‚ÇÇ clearance** and **hypercapnia**; patients often present **somnolent** with **impaired airway protection**.  
13. **Noninvasive positive-pressure ventilation (PPV)** improves **minute ventilation** and **gas exchange** and should be considered for patients who **can protect their airway**.  
14. **ABGs** should be checked **within 2 hours** of **noninvasive PPV** initiation to ensure improvement.  
15. If patients **do not improve** with adequate **noninvasive PPV**, **intubation** is warranted.  
16. If **airway protection is compromised**, or **pH <7.25** or **hemodynamic instability** is present, **intubation and mechanical ventilation** are indicated.  
17. **Respiratory stimulants** (e.g., **acetazolamide**, **theophylline**, **progestin**) have **theoretical benefit** but **limited supporting data**.

#### ‚úÖ True Statements ‚Äî Drug Overdose
18. **Sedating drugs**, **anesthetics**, and **severe alcohol intoxication** can **depress central respiratory drive**; consultation with **poison control** helps determine management.

#### ‚úÖ True Statements ‚Äî Obesity Hypoventilation Syndrome
19. **Obesity hypoventilation syndrome** is defined by **obesity (BMI ‚â•30)**, **sleep-disordered breathing**, and **persistent daytime hypercapnia (arterial PCO‚ÇÇ >45 mm Hg [6.0 kPa])**.  
20. Hypercapnia in **obesity hypoventilation syndrome** stems from **low tidal volumes** and **inappropriate central respiratory response**; **acute hypercapnic respiratory failure** from this syndrome is a **diagnosis of exclusion**.  
21. **2019 American Thoracic Society guidelines** recommend **noninvasive ventilation** (bilevel positive airway pressure or **volume-targeted pressure support**) for **hospitalized** patients suspected of **obesity hypoventilation syndrome**, continued until **outpatient evaluation for obstructive sleep apnea**.

---

### üìò Related Text Derivations

---

#### ‚úÖ True Statements ‚Äî Hypercapnic (Ventilatory) Respiratory Failure
1. **Hypercapnic (ventilatory) respiratory failure** occurs when **alveolar ventilation** is inadequate to clear **carbon dioxide (CO‚ÇÇ)** produced by cellular metabolism, resulting in **elevated arterial PCO‚ÇÇ**.  
2. **Hypercapnia** reflects **alveolar hypoventilation**, an **increased metabolic load** not matched by ventilation, or **both**.  
3. **Alveolar hypoventilation** occurs with **decreased respiratory rate**, **decreased tidal volume (VT)**, or **increased dead-space volume relative to VT (VD/VT)**.  
4. Clinical features of **acute hypercapnic respiratory failure** are **variable** and **nonspecific**; **somnolence** and **myoclonic jerks** can occur with **CO‚ÇÇ narcosis**.  
5. **Increased work of breathing** may precede the development of **acute hypercapnic respiratory failure**.  
6. **Preexisting chest wall deformity, neurologic weakness,** or **polycythemia** should prompt evaluation for **hypercapnia** in the setting of respiratory failure.  
7. Patients with **hypercapnic respiratory failure** frequently have **coexisting hypoxemia**; **supplemental oxygen** may **decrease hypoxemia** but **increase hypercapnia** via **ventilation‚Äìperfusion (V/Q) mismatch**, **decreased respiratory drive**, and the **Haldane effect**.  
8. Worsening **hypercapnia** with oxygen is **particularly problematic** for **neuromuscular diseases**, risking **obtundation** and **respiratory arrest**.  
9. **Arterial blood gas (ABG)** analysis should be obtained in **all suspected acute hypercapnic respiratory failure**, even if **hypoxemia resolves** with oxygen; **pH** helps determine **acuity and severity**.  
10. In **chronic hypercapnia**, **pH changes are less marked** because of **metabolic compensation** with **increased serum bicarbonate**.  
11. Management of **elevated arterial PCO‚ÇÇ** depends on the **clinical context** and **resultant pH**; in **COPD**, elevated PCO‚ÇÇ may be **baseline**, whereas in **asthma**, rising PCO‚ÇÇ may signal **imminent respiratory failure** requiring **emergent intubation**.

---

#### ‚úÖ True Statements ‚Äî Decreased Respiratory Drive
12. **Decreased respiratory drive** leads to **diminished alveolar CO‚ÇÇ clearance** and **hypercapnia**; patients often present **somnolent** with **impaired airway protection**.  
13. **Noninvasive positive-pressure ventilation (PPV)** improves **minute ventilation** and **gas exchange** and should be considered for patients who **can protect their airway**.  
14. **Arterial blood gases** should be checked **within 2 hours** of **noninvasive PPV** initiation to ensure improvement.  
15. If patients **do not improve** with adequate **noninvasive PPV**, **intubation** is warranted.  
16. If **airway protection is compromised**, or **pH <7.25** or **hemodynamic instability** is present, **intubation and mechanical ventilation** are indicated.  
17. **Respiratory stimulants** (e.g., **acetazolamide**, **theophylline**, **progestin**) have **theoretical benefit** but **limited supporting data**.

---

#### ‚úÖ True Statements ‚Äî Drug Overdose
18. **Sedating drugs**, **anesthetics**, and **severe alcohol intoxication** can **depress central respiratory drive**; consultation with **poison control** helps determine management.


---

#### ‚úÖ True Statements ‚Äî Obesity Hypoventilation Syndrome
19. **Obesity hypoventilation syndrome** is defined by **obesity (BMI ‚â•30)**, **sleep-disordered breathing**, and **persistent daytime hypercapnia (arterial PCO‚ÇÇ >45 mm Hg [6.0 kPa])**.  
20. Hypercapnia in **obesity hypoventilation syndrome** stems from **low tidal volumes** and **inappropriate central respiratory response**; **acute hypercapnic respiratory failure** from this syndrome is a **diagnosis of exclusion**.  
21. **2019 American Thoracic Society guidelines** recommend **noninvasive ventilation** (bilevel positive airway pressure or **volume-targeted pressure support**) for **hospitalized** patients suspected of **obesity hypoventilation syndrome**, continued until **outpatient evaluation for obstructive sleep apnea**.

---

#### ‚úÖ True Statements ‚Äî Neuromuscular Weakness
22. The **diaphragm** is the primary inspiratory muscle and accounts for **more than two thirds** of ventilatory work; it is innervated by **phrenic nerves** from **C3‚ÄìC5**.  
23. **Diaphragmatic weakness** is **common** in the ICU (e.g., **postsurgical phrenic nerve injury**, **ICU-acquired weakness**) and causes **orthopnea**, **shallow breathing**, and **paradoxical chest/abdominal motion**.  
24. **Intercostal and abdominal wall muscles** are required for **cough**; injury to lower cervical/upper thoracic roots impairs **secretion clearance**.  
25. **Bulbar weakness** (cranial nerves **IX‚ÄìXII**) can cause **weak cough**, **secretion management difficulty**, or **voice change**.  
26. **Pulmonary function testing** components are **effort-dependent** and can be affected by **facial/bulbar/postural weakness**; **pressure measurements** may be **falsely low** in **severe obstructive lung disease**.  
27. **Guillain‚ÄìBarr√© syndrome** typically presents with **ascending symmetric paralysis** and **areflexia** over **2‚Äì4 weeks**; **dysautonomia** is common and may cause **hemodynamic instability** or **arrhythmias**.  
28. About **25%** of **Guillain‚ÄìBarr√© syndrome** patients develop **respiratory failure** and require **intubation** because recovery can take **days to weeks**.  
29. In **myasthenic crisis**, **muscle fatigability** is the hallmark; **diplopia**, **ptosis**, **dysarthria**, **limb weakness**, and **weak cough** are common; **early noninvasive PPV** may prevent **intubation**, but **airway protection** and **cough** must be carefully evaluated.  
30. **Acute spinal cord injuries at or above C5** invariably require **mechanical ventilation**; recovery of independent respiration may occur in **complete injury below C3** or **incomplete injury above C3**.  
31. **Atelectasis**, **aspiration pneumonia**, and **pulmonary emboli** are **common** after **spinal cord injury** and can cause **recurrent acute hypercapnic respiratory failure**; **noninvasive PPV** and **mechanical cough assist** are **essential**.

---

#### ‚úÖ True Statements ‚Äî Restrictive Chest Wall Disease
32. **Restrictive parenchymal lung disease** primarily causes **hypoxemia** without hypercapnia; **acute hypercapnic respiratory failure** is **more common** with **extrapulmonary chest wall restriction** (e.g., **pectus deformity**, **scoliosis**, **kyphosis**).  
33. **Abdominal processes** (e.g., **ascites**, **severe pancreatitis**, **bowel distention**, **abdominal compartment syndrome** with **intra-abdominal pressure ‚â•20 mm Hg**) can compromise **respiratory mechanics** by **cephalad diaphragmatic force**.  
34. **Extrapulmonary restriction** usually causes **poor ventilatory reserve**; **acute insults** (e.g., **infection**, **sedatives**) may precipitate **hypercapnic respiratory failure**.  
35. **Noninvasive PPV** or **invasive mechanical ventilation** may be used while the **precipitating condition** is managed; in **thoracic cage deformity**, **noninvasive PPV** is **frequently sufficient**.

---

#### ‚úÖ True Statements ‚Äî Obstructive Lung Diseases (COPD and Asthma)
36. **COPD exacerbation** typically presents with **cough**, **increased or changed sputum**, and **progressive dyspnea**; **hypercapnic respiratory failure** may develop with **somnolence** and **myoclonus**.  
37. In **hypercapnic respiratory failure** from **COPD exacerbation**, **noninvasive PPV**‚Äîpreferably **bilevel positive airway pressure**‚Äîis **initial therapy** to **reduce PCO‚ÇÇ**, improving **symptoms**, **intubation rates**, **hospital stay**, and **mortality**.  
38. If COPD patients **cannot protect the airway**, are **hemodynamically unstable**, or **fail noninvasive PPV**, **intubation and mechanical ventilation** are necessary.  
39. During **COPD exacerbation**, **excessive oxygen** can **worsen hypercapnia** via **V/Q mismatch**, **reduced drive**, and the **Haldane effect**; **oxygen** should be **titrated** to **SpO‚ÇÇ 88%‚Äì92%**.  
40. In **asthma**, signs of **impending respiratory failure** include **upright posture**, **inability to speak in full sentences**, **diaphoresis**, **nasal flaring**, and **accessory muscle use**.  
41. In **asthma exacerbation**, **arterial blood gases** often show **respiratory alkalosis** from **rapid, shallow breathing**; **normalizing or rising PCO‚ÇÇ** may signal **impending respiratory failure**.  
42. **Severe asthma exacerbation** therapy includes **continuous inhaled bronchodilators**, **systemic glucocorticoids**, **intravenous fluids**, and **electrolyte correction**; **oxygen** should maintain **hemoglobin saturation 90%‚Äì95%**.  
43. If asthma is **refractory to conventional therapy**, **magnesium sulfate** or **helium-oxygen** may be considered; **aminophylline**, **mucolytics**, and **leukotriene receptor antagonists** are **not recommended** in severe refractory asthma; **antibiotics** only with **evidence of infection**.  
44. Evidence for **noninvasive PPV** in **asthma exacerbation** is **limited**; if used, **close monitoring** is required; for most with **respiratory failure**, **intubation and mechanical ventilation** are **recommended**.  
45. In **obstructive lung disease on mechanical ventilation**, **auto-PEEP** from **dynamic hyperinflation and air trapping** may reduce **venous return** and cause **hemodynamic instability**; minimizing **auto-PEEP** involves **prolonging expiratory time** (lower respiratory rate) and **bronchodilators**; doing so often requires **sedation or paralytics** and may necessitate **higher tidal volume** to maintain **minute ventilation**; **ABGs** should be **checked frequently**.

---

### üóæ Supplemental Tables

<!-- Causes of Acute Hypercapnic Respiratory Failure -->
<table>
  <caption><strong>Causes of Acute Hypercapnic Respiratory Failure</strong></caption>
  <tbody>
    <tr><th colspan="1">Decreased Respiratory Drive</th></tr>
    <tr><td>Anesthesia</td></tr>
    <tr><td>Central apnea</td></tr>
    <tr><td>Obesity hypoventilation syndrome</td></tr>
    <tr><td>Drugs (e.g., opioids, benzodiazepines, ethanol)</td></tr>
    <tr><td>Encephalitis</td></tr>
    <tr><td>Hypothermia</td></tr>
    <tr><td>Hypothyroidism</td></tr>
    <tr><td>Meningitis</td></tr>
    <tr><td>Stroke</td></tr>
    <tr><th colspan="1">Decreased V<sub>T</sub> or Increased V<sub>D</sub>/V<sub>T</sub></th></tr>
    <tr><td><em>Neuromuscular weakness</em></td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Amyotrophic lateral sclerosis</td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Botulism</td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Critical illness myopathy</td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Guillain‚ÄìBarr√© syndrome</td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Myasthenia gravis</td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Myositis (polymyositis, dermatomyositis)</td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Polio</td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Spinal or phrenic nerve injury</td></tr>
    <tr><td><em>Metabolic</em></td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Electrolyte disorder (low magnesium, low phosphate)</td></tr>
    <tr><td><em>Obstructive airway disease</em></td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Asthma exacerbation</td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Bronchiectasis flare (including cystic fibrosis)</td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;COPD exacerbation</td></tr>
    <tr><td><em>Restrictive physiology</em></td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Ankylosing spondylitis</td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Multiple rib fractures (flail chest)</td></tr>
    <tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Thoracic cage deformity (kyphoscoliosis)</td></tr>
  </tbody>
</table>
<p><em>V<sub>D</sub> = volume of dead space; V<sub>T</sub> = tidal volume.</em></p>

#### ‚úÖ True Statements (from Table: Causes of Acute Hypercapnic Respiratory Failure)
1. **Decreased respiratory drive** causes include **anesthesia**, **central apnea**, **obesity hypoventilation syndrome**, **sedatives/alcohol**, **encephalitis**, **hypothermia**, **hypothyroidism**, **meningitis**, and **stroke**.  
2. **Decreased tidal volume (VT) or increased dead-space fraction (VD/VT)** causes include **neuromuscular weakness** (ALS, botulism, critical illness myopathy, Guillain‚ÄìBarr√©, myasthenia gravis, myositis, polio, spinal/phrenic nerve injury), **metabolic electrolyte disorders** (low magnesium, low phosphate), **obstructive airway disease** (asthma, bronchiectasis, COPD), and **restrictive physiology** (ankylosing spondylitis, flail chest, kyphoscoliosis).  

---

<!-- Features of Acute and Chronic Hypercapnia -->
<table>
  <caption><strong>Features of Acute and Chronic Hypercapnia</strong></caption>
  <thead>
    <tr>
      <th>Laboratory Study</th>
      <th>Acute Hypercapnia</th>
      <th>Chronic Hypercapnia</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>pH</td>
      <td>&lt;7.35</td>
      <td>~7.35‚Äì7.40</td>
    </tr>
    <tr>
      <td>Arterial PCO<sub>2</sub></td>
      <td>&gt;45 mm Hg (6.0 kPa)</td>
      <td>&gt;45 mm Hg (6.0 kPa)</td>
    </tr>
    <tr>
      <td>Bicarbonate concentration [HCO<sub>3</sub>]</td>
      <td>22‚Äì26 mEq/L (22‚Äì26 mmol/L)</td>
      <td>&gt;26 mEq/L (26 mmol/L)</td>
    </tr>
    <tr>
      <td>Expected metabolic compensation</td>
      <td>‚Üë 1.0 mEq/L (1 mmol/L) [HCO<sub>3</sub>] for each 10 mm Hg (1.3 kPa) ‚Üë in arterial PCO<sub>2</sub></td>
      <td>‚Üë 3.5 mEq/L (3.5 mmol/L) [HCO<sub>3</sub>] for each 10 mm Hg (1.3 kPa) ‚Üë arterial PCO<sub>2</sub></td>
    </tr>
  </tbody>
</table>

#### ‚úÖ True Statements (from Table: Features of Acute and Chronic Hypercapnia)
1. **Acute hypercapnia**: **pH <7.35**, **PCO‚ÇÇ >45 mm Hg**, **HCO‚ÇÉ‚Åª 22‚Äì26 mEq/L**, expected +1.0 mEq/L HCO‚ÇÉ‚Åª per +10 mm Hg PCO‚ÇÇ.  
2. **Chronic hypercapnia**: **pH ~7.35‚Äì7.40**, **PCO‚ÇÇ >45 mm Hg**, **HCO‚ÇÉ‚Åª >26 mEq/L**, expected +3.5 mEq/L HCO‚ÇÉ‚Åª per +10 mm Hg PCO‚ÇÇ.  

---

<!-- Pulmonary Function Values Suggestive of Neuromuscular Weakness -->
<table>
  <caption><strong>Pulmonary Function Values Suggestive of Neuromuscular Weakness</strong></caption>
  <thead>
    <tr>
      <th>Function</th>
      <th>Value</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>FVC</td>
      <td>&gt;20% decrement in FVC while supine compared with upright position</td>
    </tr>
    <tr>
      <td>Maximal inspiratory pressure</td>
      <td>Less than ‚àí60 cm H<sub>2</sub>O or 50% of predicted</td>
    </tr>
    <tr>
      <td>Maximal expiratory pressure</td>
      <td>Less than +40 cm H<sub>2</sub>O or 50% of predicted</td>
    </tr>
  </tbody>
</table>
<p><em>FVC = forced vital capacity.</em></p>

#### ‚úÖ True Statements (from Table: Pulmonary Function Values Suggestive of Neuromuscular Weakness)
1. A **>20% drop in FVC** when **supine vs upright** suggests **neuromuscular weakness**.
2. **Maximal inspiratory pressure < ‚àí60 cm H‚ÇÇO** or **50% of predicted** suggests **neuromuscular weakness**.  
3. **Maximal expiratory pressure < +40 cm H‚ÇÇO** or **50% of predicted** suggests **neuromuscular weakness**.  
